Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 514

1.
2.

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.

Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, de Vries R, Balasubramanian S, Hellemans P, Smit JW, Fourneau N, Oki Y.

Lancet Oncol. 2014 Aug;15(9):1019-26. doi: 10.1016/S1470-2045(14)70311-0.

PMID:
25042202
3.

[Comparison between efficacy and safety of rituximab plus CHOP regimen and CHOP regimen for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].

Xu W, Li JY, Zhang ZH, Qiu HX, Qian SX, Wu HX, Lu H, Sheng RL.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Aug;16(4):933-7. Chinese.

PMID:
18718094
4.

Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.

Li X, Liu Z, Cao J, Hong X, Wang J, Chen F, Wang C, Zou S, Li J, Shen Z.

Ann Hematol. 2012 Jun;91(6):837-45. doi: 10.1007/s00277-011-1375-0.

PMID:
22160255
5.

R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy.

Halaas JL, Moskowitz CH, Horwitz S, Portlock C, Noy A, Straus D, O'Connor OA, Yahalom J, Zelenetz AD.

Leuk Lymphoma. 2005 Apr;46(4):541-7.

PMID:
16019482
6.

[Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].

Wu HJ, Zhang QY, Chen DF, Guan XJ, Zhang BL, Ma J.

Ai Zheng. 2005 Dec;24(12):1498-502. Chinese.

PMID:
16351800
7.

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C.

N Engl J Med. 2002 Jan 24;346(4):235-42.

8.

Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.

Abdelhamid T, Samra M, Ramadan H, Mehessin M, Mokhtar N.

J Egypt Natl Canc Inst. 2011 Mar;23(1):17-24. doi: 10.1016/j.jnci.2011.07.003.

9.

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.

Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D.

Lancet. 2013 May 25;381(9880):1817-26. doi: 10.1016/S0140-6736(13)60313-X.

10.

Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.

Avivi I, Zilberlicht A, Dann EJ, Leiba R, Faibish T, Rowe JM, Bar-Shalom R.

Am J Hematol. 2013 May;88(5):400-5. doi: 10.1002/ajh.23423.

11.

The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma.

Sohn BS, Kim SM, Yoon DH, Kim S, Lee DH, Kim JH, Lee SW, Huh J, Suh C.

Ann Hematol. 2012 Nov;91(11):1731-9. doi: 10.1007/s00277-012-1512-4.

PMID:
22752193
12.

[Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].

Lin TY, Zhang HY, Huang Y, Guan ZZ, Shen T, Shi YK, Zhu J, Ke XY, Wang HQ, Shen ZX, Yu SY, Liu T, Shi XL.

Ai Zheng. 2005 Dec;24(12):1421-6. Chinese.

PMID:
16351785
14.

Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results.

Tobinai K, Ogura M, Itoh K, Kinoshita T, Hotta T, Watanabe T, Morishima Y, Igarashi T, Terauchi T, Ohashi Y; All Collaborators of the IDEC-C2B8 Study Group in Japan..

Cancer Sci. 2010 Dec;101(12):2579-85. doi: 10.1111/j.1349-7006.2010.01703.x.

15.

Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma.

Mato A, Feldman T, Zielonka T, Singavi A, Gadaletta G, Waksmundzki K, Bhattacharyya P, Chow KF, Yang X, Panush D, Agress H, Rosario M, Howlett C, Pecora A, Goy A.

Leuk Lymphoma. 2013 Dec;54(12):2606-12. doi: 10.3109/10428194.2013.783909.

PMID:
23488604
16.

Treatment of older patients with mantle-cell lymphoma.

Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G, Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Procházka V, Di Raimondo F, Ribrag V, Uppenkamp M, André M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH.

N Engl J Med. 2012 Aug 9;367(6):520-31. doi: 10.1056/NEJMoa1200920.

17.

Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factors in 41 consecutive Asian patients.

Tai WM, Quah D, Yap SP, Tan SH, Tang T, Tay KW, Koo YX, Tao M, Quek R, Lim ST.

Leuk Lymphoma. 2011 Apr;52(4):604-12. doi: 10.3109/10428194.2010.550073.

PMID:
21261504
18.

Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases.

Li X, Shen W, Cao J, Wang J, Chen F, Wang C, Zou S, Shen B, Zhao R, Li J, Shen Z.

Ann Hematol. 2012 Nov;91(11):1721-9. doi: 10.1007/s00277-012-1507-1.

PMID:
22733613
19.

Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.

Park YH, Lee JJ, Ryu MH, Kim SY, Kim DH, Do YR, Lee KH, Oh SJ, Kim YK, Suh CW, Heo DS, Ryoo BY, Kim JK, Song HS, Lee WS, Kim HJ, Bang YJ, Yang SH, Sohn SK, Kang YK; Lymphoma Study Division of the Korean Cancer Study Group..

Ann Hematol. 2006 Apr;85(4):257-62.

PMID:
16416337
20.

Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens.

Goto N, Tsurumi H, Kasahara S, Kanemura N, Hara T, Yasuda I, Shimizu M, Murakami N, Sawada M, Yamada T, Takemura M, Seishima M, Kito Y, Takami T, Moriwaki H.

Eur J Haematol. 2011 Sep;87(3):217-27. doi: 10.1111/j.1600-0609.2011.01649.x.

PMID:
21575062
Items per page

Supplemental Content

Support Center